share_log

Guggenheim Downgrades Aerovate Therapeutics to Neutral

Benzinga ·  Jun 18 12:51

Guggenheim analyst Vamil Divan downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment